Business Description
Black Diamond Therapeutics is a Cambridge, Massachusetts-based drug development company working to create targeted cancer treatments for patients whose tumors are driven by specific genetic mutations. Its most advanced drug, silevertinib, is currently being tested in two Phase 2 trials for lung cancer and brain tumors, while two additional compounds targeting other cancer-causing genetic changes are progressing through earlier stages of development. Founded in 2014, the company's approach centers on building treatments broad enough to address a wide range of related mutations within a given cancer type, rather than targeting a single genetic variant.
